Our data support this notion and suggest that antiviral treatment alone is not sufficient to treat HSE, and that a combinatorial therapy with anti-inflammatory drugs targeting the TNF–NF-κB pathway may be a valuable addition to current therapeutic approaches. This evidence concerns the gene NFKB1 and herpes simplex encephalitis.